KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas.

Nicolai A. Schultz,Anne Roslind,Mel C. Heeran,Ib Jarle Christensen,Estrid Høgdall,Thomas Horn,Morten Wøjdemann,Eva Balslev,Julia S. Johansen

KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas.

2010

Nicolai A. Schultz
Anne Roslind
Mel C. Heeran
Ib Jarle Christensen
Estrid Høgdall
Thomas Horn
Morten Wøjdemann
Eva Balslev
Julia S. Johansen

4043 Background: The results of cytostatic treatment in pancreatic ductal adenocarcinomas (PDAC) are still disappointing. Standard treatment is still gemcitabine, monotherapy or in combinations. St...

Keywords:

Pathology
KRAS
Cancer research
Medicine
Gemcitabine
in patient
her2 expression
pancreatic ductal
Standard treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations